LFCR
Price
$7.88
Change
+$0.42 (+5.63%)
Updated
Jan 14 closing price
Capitalization
294.86M
Earnings call today
Intraday BUY SELL Signals
RDY
Price
$13.30
Change
+$0.08 (+0.61%)
Updated
Jan 14 closing price
Capitalization
10.94B
6 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

LFCR vs RDY

Header iconLFCR vs RDY Comparison
Open Charts LFCR vs RDYBanner chart's image
Lifecore Biomedical
Price$7.88
Change+$0.42 (+5.63%)
Volume$129.93K
Capitalization294.86M
Dr. Reddy's Laboratories
Price$13.30
Change+$0.08 (+0.61%)
Volume$1.12M
Capitalization10.94B
LFCR vs RDY Comparison Chart in %
LFCR
Daily Signal:
Gain/Loss:
RDY
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
LFCR vs. RDY commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LFCR is a Hold and RDY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (LFCR: $7.88 vs. RDY: $13.30)
Brand notoriety: LFCR and RDY are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: LFCR: 79% vs. RDY: 102%
Market capitalization -- LFCR: $294.86M vs. RDY: $10.94B
LFCR [@Pharmaceuticals: Generic] is valued at $294.86M. RDY’s [@Pharmaceuticals: Generic] market capitalization is $10.94B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $65.17B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.59B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LFCR’s FA Score shows that 1 FA rating(s) are green whileRDY’s FA Score has 0 green FA rating(s).

  • LFCR’s FA Score: 1 green, 4 red.
  • RDY’s FA Score: 0 green, 5 red.
According to our system of comparison, LFCR is a better buy in the long-term than RDY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LFCR’s TA Score shows that 5 TA indicator(s) are bullish while RDY’s TA Score has 5 bullish TA indicator(s).

  • LFCR’s TA Score: 5 bullish, 4 bearish.
  • RDY’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, LFCR is a better buy in the short-term than RDY.

Price Growth

LFCR (@Pharmaceuticals: Generic) experienced а -0.13% price change this week, while RDY (@Pharmaceuticals: Generic) price change was -2.78% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.60%. For the same industry, the average monthly price growth was +8.77%, and the average quarterly price growth was +19.20%.

Reported Earning Dates

LFCR is expected to report earnings on Jan 15, 2026.

RDY is expected to report earnings on Jan 21, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.60% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RDY($10.9B) has a higher market cap than LFCR($295M). LFCR has higher P/E ratio than RDY: LFCR (51.23) vs RDY (17.08). LFCR YTD gains are higher at: -3.667 vs. RDY (-5.271). RDY has higher annual earnings (EBITDA): 98.5B vs. LFCR (-8.81M). RDY has more cash in the bank: 69.8B vs. LFCR (18.9M). LFCR has less debt than RDY: LFCR (136M) vs RDY (58.5B). RDY has higher revenues than LFCR: RDY (342B) vs LFCR (129M).
LFCRRDYLFCR / RDY
Capitalization295M10.9B3%
EBITDA-8.81M98.5B-0%
Gain YTD-3.667-5.27170%
P/E Ratio51.2317.08300%
Revenue129M342B0%
Total Cash18.9M69.8B0%
Total Debt136M58.5B0%
FUNDAMENTALS RATINGS
LFCR vs RDY: Fundamental Ratings
LFCR
RDY
OUTLOOK RATING
1..100
6768
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
10079
SMR RATING
1..100
10051
PRICE GROWTH RATING
1..100
5476
P/E GROWTH RATING
1..100
671
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RDY's Valuation (79) in the Pharmaceuticals Generic industry is in the same range as LFCR (95) in the Industrial Specialties industry. This means that RDY’s stock grew similarly to LFCR’s over the last 12 months.

RDY's Profit vs Risk Rating (79) in the Pharmaceuticals Generic industry is in the same range as LFCR (100) in the Industrial Specialties industry. This means that RDY’s stock grew similarly to LFCR’s over the last 12 months.

RDY's SMR Rating (51) in the Pharmaceuticals Generic industry is somewhat better than the same rating for LFCR (100) in the Industrial Specialties industry. This means that RDY’s stock grew somewhat faster than LFCR’s over the last 12 months.

LFCR's Price Growth Rating (54) in the Industrial Specialties industry is in the same range as RDY (76) in the Pharmaceuticals Generic industry. This means that LFCR’s stock grew similarly to RDY’s over the last 12 months.

LFCR's P/E Growth Rating (6) in the Industrial Specialties industry is somewhat better than the same rating for RDY (71) in the Pharmaceuticals Generic industry. This means that LFCR’s stock grew somewhat faster than RDY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LFCRRDY
RSI
ODDS (%)
Bearish Trend 1 day ago
71%
Bullish Trend 1 day ago
70%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
61%
Momentum
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
48%
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
53%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
51%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
46%
Advances
ODDS (%)
Bullish Trend 21 days ago
76%
Bullish Trend 4 days ago
47%
Declines
ODDS (%)
Bearish Trend 7 days ago
77%
Bearish Trend 8 days ago
54%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
76%
Aroon
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
38%
View a ticker or compare two or three
Interact to see
Advertisement
LFCR
Daily Signal:
Gain/Loss:
RDY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MMSMY29.211.06
+3.77%
Mitsu Mining & Smelting Co., Ltd.
ASCN117.71N/A
N/A
Absecon Bancorp
PINXY17.43N/A
N/A
Peoples Insurance Company Group China
TUWLF0.08N/A
N/A
Tullow Oil Plc.
TAOFF4.52N/A
N/A
IPERIONX LTD.

LFCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, LFCR has been loosely correlated with NBIX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if LFCR jumps, then NBIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LFCR
1D Price
Change %
LFCR100%
+5.63%
NBIX - LFCR
36%
Loosely correlated
+2.32%
AMRX - LFCR
32%
Poorly correlated
+2.16%
SHPH - LFCR
31%
Poorly correlated
+6.29%
ZTS - LFCR
30%
Poorly correlated
+0.98%
PBH - LFCR
29%
Poorly correlated
+0.14%
More

RDY and

Correlation & Price change

A.I.dvisor tells us that RDY and COLL have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RDY and COLL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RDY
1D Price
Change %
RDY100%
+0.61%
COLL - RDY
30%
Poorly correlated
-1.50%
AVDL - RDY
28%
Poorly correlated
+0.09%
LFCR - RDY
28%
Poorly correlated
+5.63%
TAK - RDY
27%
Poorly correlated
+2.87%
HROW - RDY
27%
Poorly correlated
+2.06%
More